Skip to main content

Advertisement

Table 5 Overall survival analysis

From: Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy

Dichotomized variables Associated level OS
   Hazard ratio (95% CI) p-value
Univariate analysis    
Age > 66 years 0.971 (0.514-1.834) 0.9288
Sex Male 1.967 (1.033-3.748) 0.0396
KPS > 50 0.539 (0.283-1.029) 0.0611
Histology Adenocarcinoma 0.965 (0.510-1.825) 0.9118
Presence of liver metastasis Yes 0.982 (0.463-2.082) 0.9616
Use of chemotherapy before hRT Yes 1.085 (0.572-2.057) 0.8034
Time from first diagnosis to hRT ≥ 12 months 0.804 (0.424-1.524) 0.5037
Other RT prior to hRT Yes 1.411 (0.656-3.034) 0.3785
Use of any other hemostatic measure Yes 1.056 (0.409-2.724) 0.9105
Bleeding cause Primary tumor 1.420 (0.623-3.236) 0.4036
WHO bleeding score before hRT Grade 3 1.380 (0.728-2.617) 0.3239
Dose of hRT < 30 Gy 2.669 (1.286-5.540) 0.0084
WHO bleeding score at end of hRT Grade 2-4 5.882 (2.445-13.865) <0.0001
WHO bleeding score at end of follow-up Grade 2-4 2.006 (0.969-4.154) 0.0609
Multivariate analysis    
Sex Male 1.007 (0.487-2.081) 0.9859
Dose of hRT < 30 Gy 2.853 (1.360-5.987) 0.0056
WHO bleeding score at end of hRT Grade 2-4 6.456 (2.645-16.202) <0.0001
  1. Abbreviations: RT=radiotherapy; hRT=hemostatic radiotherapy; KPS=Karnowsky performance score; OS=overall survival.